Pacira BioSciences, Inc. ( PCRX Quick Quote PCRX - Free Report) reported second-quarter 2021 earnings of 77 cents per share, beating the Zacks Consensus Estimate of 76 cents. The company reported earnings of 12 cents per share in the year-ago quarter.
Total revenues surged 79.6% to $135.6 million in the second quarter of 2021 from the year-earlier figure of $75.5 million, owing to strong uptake of Exparel. The top line also surpassed the Zacks Consensus Estimate of $134 million.
Shares of Pacira were up 2.7% on Tuesday following the announcement of better-than-expected earnings results. The stock has rallied 1.6% so far this year against the
industry’s decrease of 11.1%. Image Source: Zacks Investment Research Quarter in Detail
Pacira’s top line mainly comprises of product revenues, other product sales and royalty revenues.
Exparel net product sales were $130.1 million, up 78.2% from $73 million generated in the year-ago quarter. Sale of the drug also increased 13.4% on a sequential basis.
Exparel/bupivacaine liposome injectable suspension sales came in at $1 million in the reported quarter compared with $0.8 million in the year-ago quarter. Exparel is a liposome injection of bupivacaine, indicated for a single-dose administration into the surgical site to produce postsurgical analgesia. Iovera system generated sales worth $3.8 million in the second quarter of 2021, reflecting a sequential increase of 15.1%.
Royalty revenues came in at $0.7 million in the reported quarter compared with $0.3 million reported in the year-ago quarter.
Research and development (R&D) expenses (excluding stock-based compensation) declined approximately 8.2% to $11.2 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) increased around 17.4% year over year to $43.1 million in the reported quarter.
Pacira is not providing guidance for 2021 due to the COVID-19 pandemic still negatively impacting sales. As a result, it is reporting monthly intra-quarter unaudited net product sales until the company gains enough visibility around the impacts of COVID-19.
In July 2021, the FDA approved Pacira’s enhanced manufacturing process for Exparel at a custom facility in Swindon, England under a partnership with Thermo Fisher Scientific Pharma Services. The company plans to start selling products manufactured at this suite later in 2021.
In May 2021, Pacira announced top-line data from the phase III STRIDE study which evaluated Exparel as a lower-extremity nerve block. In the study, Exparel did not demonstrate statistical significance of cumulative pain reduction from zero to 96 hours versus bupivacaine HCl – the primary endpoint of the study.
However, treatment with Exparel did demonstrate statistical significance versus bupivacaine HCl of reducing cumulative pain scores from 24 to 96 hours post-surgery and total opioid consumption from 24 to 96 hours post-surgery – the secondary endpoints. Exparel also achieved statistical significance versus bupivacaine HCl for area under the curve cumulative pain scores from 12 to 96 hours.
In March 2021, the FDA
approved Pacira’s supplemental new drug application (sNDA) seeking approval of Exparel for use in children aged six years and above. The label expansion should boost Exparel sales in the future quarters. Pacira BioSciences, Inc. Price, Consensus and EPS Surprise Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include
CanFite Biopharma Ltd ( CANF Quick Quote CANF - Free Report) , Ironwood Pharmaceuticals, Inc. ( IRWD Quick Quote IRWD - Free Report) and Theravance Biopharma, Inc. ( TBPH Quick Quote TBPH - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
CanFite Biopharma’s loss per share estimates have narrowed 26.8% for 2021 and 48% for 2022 over the past 60 days. The stock has soared 16.8% year to date.
Ironwood’s earnings estimates have been revised 3.8% upward for 2021 and 1.7% upward for 2022 over the past 60 days. The stock has rallied 14.2% year to date.
Theravance’s loss per share estimates have narrowed 5.2% for 2021 and 11.6% for 2022 over the past 60 days. The stock has rallied 50% year to date.